Key result
AYUSH immune boosters show ~89% utilization among surveyed NCD patients during the pandemic.
Why the study?
The impact of COVID-19 on patients with NCDs regarding knowledge, awareness, perception, AYUSH immune booster use, and chronic condition management needed to be determined.
Cross-Sectional (n=499)
Yes
During the COVID-19 pandemic, a large majority of Indian patients with chronic diseases demonstrated good awareness and high utilization of AYUSH immune boosters.
Answers are grounded in this paper and cite their sources.
High AYUSH use in Indian NCD patients supports awareness research; leaves open efficacy, safety, and integration questions.
OBJECTIVE: The objective of this study was to determine the impact of COVID-19 in patients suffering from NCDs in terms of their knowledge, awareness, perception about COVID-19, use of AYUSH immune boosters (AIB), and management of chronic condition during the pandemic. METHOD: During the unlock down period (October 2020), a cross-sectional study was conducted in the Krishna and Darjeeling district of Andhra Pradesh and West Bengal, India. 499 individuals suffering from at least one chronic disease were interviewed using a structured questionnaire. Logistic regression was applied to investigate the relationship of socio-demographic characteristics, AIB, and morbidity with pandemic-related care challenges. Principal component analysis was applied to minimize the dimensionality of factors related to COVID care challenges. RESULTS: 499 individuals were surveyed. 91% identified at least three correct COVID appropriate behaviours. 92.2% considered the coronavirus to be a potential threat (mean ± SD: 5.8 ± 2.6). 44.7% and 55.3% lived with one and 2 or more chronic conditions, respectively. Hypertension alone (27.4%) and diabetes with hypertension (33%) were leading presentations. Out of 499, participants, 88.8% had at least one form of AIB. 52% took Ars. alb. with other AIB and 40% took Ars. alb. alone. Only 9 participants were infected with COVID-19. CONCLUSION: In the interest of a densely populated country like India, the inclusion of simple and safe AYUSH measures is realistic, ethical, and cost-effective. AYUSH interventions as COVID-19 prophylactic and treatment as well as integrative care of chronic illnesses such as NCDs are suggested.
No takes yet. Share an insight, caveat, or question.
Varanasi et al. (2022) conducted a cross-sectional in Non-Communicable Diseases (n=499). AYUSH immune boosters (AIB) was evaluated on Knowledge, awareness, perception about COVID-19, use of AYUSH immune boosters, and management of chronic condition. AYUSH immune boosters were utilized by 88.8% of 499 surveyed patients with non-communicable diseases during the pandemic, with 91% demonstrating correct COVID-19 appropriate behaviors.
Synapse has enriched 10 related papers. Consider them for comparative context: